NASDAQ:ALRN - Aileron Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.14 +0.04 (+0.78 %)
(As of 05/22/2018 01:37 PM ET)
Previous Close$5.25
Today's Range$5.14 - $5.25
52-Week Range$5.01 - $15.48
Volume110 shs
Average Volume22,148 shs
Market Capitalization$76.49 million
P/E Ratio-2.92
Dividend YieldN/A
BetaN/A

About Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics logoAileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900

Debt

Debt-to-Equity RatioN/A
Current Ratio9.16
Quick Ratio9.16

Price-To-Earnings

Trailing P/E Ratio-2.92
Forward P/E Ratio-2.42
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.25 per share
Price / Book1.58

Profitability

EPS (Most Recent Fiscal Year)($1.77)
Net Income$-22,600,000.00
Net MarginsN/A
Return on Equity-461.02%
Return on Assets-58.75%

Miscellaneous

Employees13
Outstanding Shares14,740,000

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics (NASDAQ:ALRN) issued its earnings results on Wednesday, May, 9th. The company reported ($0.52) EPS for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.02. View Aileron Therapeutics' Earnings History.

What price target have analysts set for ALRN?

4 brokerages have issued 1 year target prices for Aileron Therapeutics' stock. Their predictions range from $19.00 to $20.00. On average, they expect Aileron Therapeutics' share price to reach $19.3333 in the next twelve months. View Analyst Ratings for Aileron Therapeutics.

Who are some of Aileron Therapeutics' key competitors?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:
  • Mr. Joseph A. Yanchik III, Founder, Pres, CEO & Director (Age 54)
  • Dr. Manuel C. Aivado, Sr. VP, Chief Medical Officer & Chief Scientific Officer (Age 48)
  • Mr. Huw M. Nash Ph.D., Co-Founder
  • Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 59)
  • Ms. Kira A. Nelson CPA, VP of Fin. & Operations (Age 49)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Has Aileron Therapeutics been receiving favorable news coverage?

Press coverage about ALRN stock has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aileron Therapeutics earned a news sentiment score of 0.19 on Accern's scale. They also gave press coverage about the company an impact score of 47.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.13%). Company insiders that own Aileron Therapeutics stock include Apple Tree Partners Ii Lp, Cvf, Llc, Lilly Ventures Fund I Llc and Reinhard J Ambros. View Institutional Ownership Trends for Aileron Therapeutics.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Cvf, Llc, Lilly Ventures Fund I Llc and Reinhard J Ambros. View Insider Buying and Selling for Aileron Therapeutics.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $5.16.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $76.49 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 281 ALBANY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-995-0900 or via email at [email protected]


MarketBeat Community Rating for Aileron Therapeutics (ALRN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  137
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Aileron Therapeutics (NASDAQ:ALRN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Aileron Therapeutics in the last 12 months. Their average twelve-month price target is $19.3333, suggesting that the stock has a possible upside of 276.13%. The high price target for ALRN is $20.00 and the low price target for ALRN is $19.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.3333$19.3333$19.3333$19.3333
Price Target Upside: 276.13% upside57.82% upside57.82% upside57.82% upside

Aileron Therapeutics (NASDAQ:ALRN) Consensus Price Target History

Price Target History for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ:ALRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2017Canaccord GenuityReiterated RatingBuy$19.00LowView Rating Details
7/24/2017William BlairInitiated CoverageOutperform ➝ OutperformHighView Rating Details
7/24/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$19.00HighView Rating Details
7/24/2017Jefferies GroupInitiated CoverageBuy ➝ Buy$20.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Aileron Therapeutics (NASDAQ:ALRN) Earnings History and Estimates Chart

Earnings by Quarter for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ:ALRN) Earnings Estimates

2018 EPS Consensus Estimate: ($2.13)
2019 EPS Consensus Estimate: ($2.23)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.50)($0.48)($0.49)
Q2 20182($0.54)($0.49)($0.52)
Q3 20182($0.58)($0.51)($0.55)
Q4 20182($0.62)($0.53)($0.58)
Q1 20191($0.54)($0.54)($0.54)
Q2 20191($0.55)($0.55)($0.55)
Q3 20191($0.56)($0.56)($0.56)
Q4 20191($0.58)($0.58)($0.58)

Aileron Therapeutics (NASDAQ ALRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.4970)($0.52)ViewN/AView Earnings Details
4/2/2018Q4 2017($0.4370)($0.47)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.36)($0.43)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.43)($0.45)ViewN/AView Earnings Details
2/8/2013Q3 2012($0.07)ViewN/AView Earnings Details
11/12/2012Q312($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Aileron Therapeutics (NASDAQ:ALRN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Aileron Therapeutics (NASDAQ ALRN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 6.79%
Insider Trading History for Aileron Therapeutics (NASDAQ:ALRN)
Institutional Ownership by Quarter for Aileron Therapeutics (NASDAQ:ALRN)

Aileron Therapeutics (NASDAQ ALRN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/19/2018Apple Tree Partners Ii LpMajor ShareholderSell107,904$6.31$680,874.24View SEC Filing  
1/9/2018Apple Tree Partners Ii LpMajor ShareholderSell150,000$9.80$1,470,000.00View SEC Filing  
7/5/2017Cvf, LlcMajor ShareholderBuy180,000$15.00$2,700,000.00View SEC Filing  
7/5/2017Lilly Ventures Fund I LlcInsiderBuy250,000$15.00$3,750,000.00View SEC Filing  
7/5/2017Reinhard J AmbrosDirectorBuy266,667$15.00$4,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Aileron Therapeutics (NASDAQ ALRN) News Headlines

Source:
DateHeadline
Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer InstituteAileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute
finance.yahoo.com - May 22 at 8:26 AM
Comparing Adamis Pharmaceuticals (ADMP) and Aileron Therapeutics (ALRN)Comparing Adamis Pharmaceuticals (ADMP) and Aileron Therapeutics (ALRN)
www.americanbankingnews.com - May 18 at 10:51 AM
Aileron Therapeutics (ALRN) CEO ResignsAileron Therapeutics (ALRN) CEO Resigns
www.streetinsider.com - May 16 at 8:31 AM
Aileron Therapeutics Announces Changes to ManagementAileron Therapeutics Announces Changes to Management
finance.yahoo.com - May 15 at 5:41 PM
-$0.51 EPS Expected for Aileron Therapeutics (ALRN) This Quarter-$0.51 EPS Expected for Aileron Therapeutics (ALRN) This Quarter
www.americanbankingnews.com - May 12 at 10:49 AM
Aileron Therapeutics (ALRN) Issues  Earnings ResultsAileron Therapeutics (ALRN) Issues Earnings Results
www.americanbankingnews.com - May 10 at 6:12 PM
Aileron Therapeutics Reports First Quarter 2018 Financial ResultsAileron Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 5:25 PM
Aileron Therapeutics (ALRN) Upgraded by ValuEngine to "Hold"Aileron Therapeutics (ALRN) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 4 at 12:54 AM
Aileron Therapeutics (ALRN) Receives Consensus Rating of "Buy" from AnalystsAileron Therapeutics (ALRN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 2 at 3:34 AM
Brokerages Anticipate Aileron Therapeutics (ALRN) to Post ($0.49) EPSBrokerages Anticipate Aileron Therapeutics (ALRN) to Post ($0.49) EPS
www.americanbankingnews.com - April 28 at 7:38 AM
Aileron Therapeutics (ALRN) Expected to Announce Earnings of -$0.49 Per ShareAileron Therapeutics (ALRN) Expected to Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - April 24 at 7:20 PM
Apple Tree Partners Ii Lp Sells 107,904 Shares of Aileron Therapeutics (ALRN) StockApple Tree Partners Ii Lp Sells 107,904 Shares of Aileron Therapeutics (ALRN) Stock
www.americanbankingnews.com - April 19 at 10:10 PM
Aileron Therapeutics (ALRN) Receives New Coverage from Analysts at Jefferies GroupAileron Therapeutics (ALRN) Receives New Coverage from Analysts at Jefferies Group
www.americanbankingnews.com - April 16 at 10:54 PM
Bank of America Initiates Coverage on Aileron Therapeutics (ALRN)Bank of America Initiates Coverage on Aileron Therapeutics (ALRN)
www.americanbankingnews.com - April 16 at 10:22 PM
Canaccord Genuity Begins Coverage on Aileron Therapeutics (ALRN)Canaccord Genuity Begins Coverage on Aileron Therapeutics (ALRN)
www.americanbankingnews.com - April 16 at 10:22 PM
Contrasting Aileron Therapeutics (ALRN) & Aeglea Bio Therapeutics (AGLE)Contrasting Aileron Therapeutics (ALRN) & Aeglea Bio Therapeutics (AGLE)
www.americanbankingnews.com - April 16 at 5:21 AM
 Aileron Therapeutics (ALRN) Given Consensus Recommendation of "Strong Buy" by Analysts Aileron Therapeutics (ALRN) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - April 13 at 3:29 AM
Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid LeukemiaAileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia
finance.yahoo.com - April 11 at 5:19 PM
Analysts Offer Predictions for Aileron Therapeutics Q1 2018 Earnings (ALRN)Analysts Offer Predictions for Aileron Therapeutics' Q1 2018 Earnings (ALRN)
www.americanbankingnews.com - April 6 at 6:48 AM
Aileron Therapeutics to Post FY2022 Earnings of ($0.01) Per Share, Jefferies Group Forecasts (ALRN)Aileron Therapeutics to Post FY2022 Earnings of ($0.01) Per Share, Jefferies Group Forecasts (ALRN)
www.americanbankingnews.com - April 5 at 8:46 AM
Aileron Therapeutics (ALRN) Expected to Post Q1 2018 Earnings of ($0.48) Per ShareAileron Therapeutics (ALRN) Expected to Post Q1 2018 Earnings of ($0.48) Per Share
www.americanbankingnews.com - April 5 at 8:37 AM
Brokers Set Expectations for Aileron Therapeutics Q1 2019 Earnings (ALRN)Brokers Set Expectations for Aileron Therapeutics' Q1 2019 Earnings (ALRN)
www.americanbankingnews.com - April 4 at 7:59 AM
Aileron Therapeutics misses by $0.01Aileron Therapeutics misses by $0.01
seekingalpha.com - April 3 at 8:35 AM
Aileron Therapeutics (ALRN) Issues  Earnings Results, Misses Expectations By $0.03 EPSAileron Therapeutics (ALRN) Issues Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - April 3 at 7:35 AM
Zacks: Aileron Therapeutics (ALRN) Given Average Rating of "Strong Buy" by BrokeragesZacks: Aileron Therapeutics (ALRN) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - March 29 at 10:28 AM
Aileron Therapeutics Announces Expansion of Scientific Advisory BoardAileron Therapeutics Announces Expansion of Scientific Advisory Board
finance.yahoo.com - March 28 at 8:39 AM
Zacks: Aileron Therapeutics (ALRN) Receives Consensus Recommendation of "Strong Buy" from AnalystsZacks: Aileron Therapeutics (ALRN) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 25 at 7:40 AM
Reviewing Aileron Therapeutics (ALRN) and Johnson & Johnson (JNJ)Reviewing Aileron Therapeutics (ALRN) and Johnson & Johnson (JNJ)
www.americanbankingnews.com - March 23 at 5:16 AM
Zacks: Analysts Set $19.33 Price Target for Aileron Therapeutics (ALRN)Zacks: Analysts Set $19.33 Price Target for Aileron Therapeutics (ALRN)
www.americanbankingnews.com - March 21 at 3:28 AM
Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of DirectorsAileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors
finance.yahoo.com - March 19 at 8:33 AM
 Brokerages Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN) Brokerages Set $19.33 Target Price for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - March 6 at 11:50 AM
Brokerages Expect Aileron Therapeutics Inc (ALRN) to Announce ($0.46) EPSBrokerages Expect Aileron Therapeutics Inc (ALRN) to Announce ($0.46) EPS
www.americanbankingnews.com - February 19 at 1:32 AM
-$0.46 EPS Expected for Aileron Therapeutics Inc (ALRN) This Quarter-$0.46 EPS Expected for Aileron Therapeutics Inc (ALRN) This Quarter
www.americanbankingnews.com - February 16 at 1:22 AM
 Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Brokerages Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - February 4 at 3:06 PM
Zacks: Analysts Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 Earnings Per ShareZacks: Analysts Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 Earnings Per Share
www.americanbankingnews.com - January 30 at 1:16 AM
Zacks: Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by BrokeragesZacks: Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 20 at 9:36 PM
 Aileron Therapeutics Inc (ALRN) Given $19.33 Average Price Target by Analysts Aileron Therapeutics Inc (ALRN) Given $19.33 Average Price Target by Analysts
www.americanbankingnews.com - January 17 at 5:42 AM
 Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Analysts Aileron Therapeutics Inc (ALRN) Given $19.33 Consensus Target Price by Analysts
www.americanbankingnews.com - January 13 at 1:58 PM
 Brokerages Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 EPS Brokerages Expect Aileron Therapeutics Inc (ALRN) to Post -$0.46 EPS
www.americanbankingnews.com - January 13 at 3:28 AM
Insider Selling: Aileron Therapeutics Inc (ALRN) Major Shareholder Sells 150,000 Shares of StockInsider Selling: Aileron Therapeutics Inc (ALRN) Major Shareholder Sells 150,000 Shares of Stock
www.americanbankingnews.com - January 11 at 6:38 PM
Aileron Therapeutics (ALRN) Lifted to Hold at Zacks Investment ResearchAileron Therapeutics (ALRN) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 10 at 5:26 PM
Zacks: Aileron Therapeutics Inc (ALRN) Given Average Rating of "Strong Buy" by BrokeragesZacks: Aileron Therapeutics Inc (ALRN) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - December 28 at 1:38 AM
Critical Analysis: Aileron Therapeutics (ALRN) versus The CompetitionCritical Analysis: Aileron Therapeutics (ALRN) versus The Competition
www.americanbankingnews.com - December 25 at 7:29 PM
Aileron Therapeutics Incs Lock-Up Period To End  on December 26th (NASDAQ:ALRN)Aileron Therapeutics Inc's Lock-Up Period To End on December 26th (NASDAQ:ALRN)
www.americanbankingnews.com - December 19 at 1:14 AM
 Analysts Set $19.33 Price Target for Aileron Therapeutics Inc (ALRN) Analysts Set $19.33 Price Target for Aileron Therapeutics Inc (ALRN)
www.americanbankingnews.com - December 13 at 7:54 AM
Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology MeetingAileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting
finance.yahoo.com - December 11 at 6:02 PM
Zacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of "Strong Buy" from AnalystsZacks: Aileron Therapeutics, Inc. (ALRN) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 5 at 1:36 AM
 Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Analysts Aileron Therapeutics, Inc. (ALRN) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - November 19 at 1:38 PM
Aileron Therapeutics Is Now Oversold (ALRN)Aileron Therapeutics Is Now Oversold (ALRN)
www.thestreet.com - November 16 at 11:03 AM
Zacks: Brokerages Set $19.33 Price Target for Aileron Therapeutics, Inc. (ALRN)Zacks: Brokerages Set $19.33 Price Target for Aileron Therapeutics, Inc. (ALRN)
www.americanbankingnews.com - November 15 at 5:08 AM

SEC Filings

Aileron Therapeutics (NASDAQ:ALRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Aileron Therapeutics (NASDAQ:ALRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Aileron Therapeutics (NASDAQ ALRN) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.